[Prognosis and therapy of malignant non-Hodgkin's lymphoma].
Rarely low malignant Non-Hodgkin-lymphomas (NHL) can be attended curatively. An alternative to hitherto applied chemotherapy in advanced stages is the retarded therapeutic proceeding in the so-called "indolent" NHL. However, the optimal therapeutic regimen is unknown. High malignant NHL can be attended curatively to a high percentage. With protocols of therapy in 2. and 3. generation the total remission rate could be increased and the rate of relapses could be decreased compared with the CHOP-scheme. The application of radiotherapy is not defined sufficiently in high malignant NHL yet.
Brockmann
B
B
Riessbeck
K H
KH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis
Zur Prognose und Therapie der malignen Non-Hodgkin-Lymphome.